ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2021 Congress

Hemophilia and Rare Bleeding Disorders » Hemophilia - Basic

Theme Navigation

  • ISTH 2021 Congress
    • Hemophilia and Rare Bleeding Disorders
      • Hemophilia - Basic

Abstract Number: PB0491

A Review Following Implemented Training for Health Care Practitioners in Primary Care Settings of Immunisation Practice in Children with Bleeding Disorders

M. Eales1, A. Wilkinson1, S. Pool2, G.W Hall1, N. Bhatnagar1

Abstract Number: PB0493

Acute Myelogenous Leukemia in a Patient with Mild Haemophilia A. A Case Report at Hospital Infantil de México Federico Gómez

L.M. Muñoz Juárez Díaz1, A.M. Moreno Gonzalez1, L. Velázquez Marmolejo1

Abstract Number: OC 24.4

Altered vWF-FVIII Binding Modulates the Factor VIII Immune Response

S.M. Zintner1, R.J. Davidson1, A.R. Wilhelm1, R.M. Camire1,2,3, L.A. George1,3,2

Abstract Number: PB0481

Analysis of the Percentage of Persons with Severe Hemophilia A as an Indicator of Care

E. Tootoonchian1, J. Stonebraker2, M. El Ekiaby3, E. Gouider4, A. Iorio5, M. Makris6, J. O'Hara7, M. Recht8, G. Pierce1, D. Coffin1

Abstract Number: PB0476

Association between Factor VIII Deficiency and Low Bone Mineral Density in Children with Hemophilia

O.U. Galindo-Aguilar1, P.A. García-Hernández2, J.Á. Garza3, D. Garay-Mendoza4, M. Ortiz-Castillo5, A. González-Martínez5, A.J. Bautista-Gómez5, G. González-Martínez5, J.F. Molina-de la Garza5, L. Villarreal Martínez5

Abstract Number: OC 38.3

BAFF Inhibition Prevents FVIII Inhibitor Formation in a Marginal Zone B Cell-independent Manner

B. Doshi1,2, M. Shaheen2, V. Arruda1,2

Abstract Number: OC 49.1

Bone Disease in Hemophilia: The Role of Different Bone Cells

S. Lancellotti1, G. Battafarano2, M. Sacco3, M. Tardugno3, L. Di Gennaro1, R. De Cristofaro1,3, A. Del Fattore2

Abstract Number: PB0486

Characteristics of Anti-drug Antibody against Emicizumab Analyzed Using Hemophilia A Patient-derived Plasma Samples

R. Kawasaki1, M. Kaneda2, M. Noguchi1, N. Matsumoto1, H. Abe1, Y. Tashiro1, Y. Inokuchi1, H. Yasuno1, T. Soeda1, Y. Yoshimura1, T. Oka2

Abstract Number: PB0473

Clinical Characteristics and Incidence of Inhibitors in Previously Untreated Children with Haemophilia: An Update of the Hemfil Cohort Study

L.L. Jardim1,2, M. Antônio Portugal Santana33, D. Gonçalves Chaves4, L. Werneck Zucheratto1, M. Hermida Cerqueira5, C. Santos Lorenzato6, V. Franco7, J. van der Bom2, S. Meireles Rezende1

Abstract Number: PB0492

Clinical Profile and Bleeding Outcome of Pediatric Hemophilia A: The Royal Hospital’s Experience, Oman

A. Al Rawahi1, F. Al Riyami2, I. Al Ghaithi3, H. Al Shukaili4, M. Al Abri4, A. Al Rawahi5

Abstract Number: OC 56.2

Comparative Analysis of Residual Factor VIII Expression from Recurrent F8 Nonsense Mutations Indicates that Localization in the B-domain Favours Readthrough-mediated Protein Output

M.F. Testa1, S. Lombardi1, M. Ferrarese1, P. Radossi2, D. Belvini2, G. Castaman3, F. Bernardi1, M. Pinotti1, A. Branchini1

Abstract Number: PB0471

Comparative Recovery of FVIII Antigen with Various FVIII Therapeutic Concentrates Using an Improved 2nd Generation ELISA Kit

R. Ni1, P. Erb1, J. Della Maestra1, H. Atkinson2, D. Foulon1, K.M Black3, H. Hoogendoorn1, D. Matino2,4

Abstract Number: OC 56.1

Deep Molecular Mechanisms of F8 exon 19 Variants and Translational Approaches in Hemophilia A

S. Lombardi1, L. Peretto1, S. Merlin2, A. Follenzi2, J.H. McVey3, I. Maestri1, F. Bernardi1, M. Pinotti1, D. Balestra1

Abstract Number: PB0477

Differences in Thrombin Generating Capacity in Severe Haemophilia A

C. Hamid1,2, J. Dunster3, E. Aradom1, J. McVey4, P. Chowdary1,2

Abstract Number: PB0469

Dose Selection for Subcutaneous Marzeptacog Alfa (Activated) in Subjects with Factor Vll Deficiency Using Population Pharmacometric Clinical Trial Simulations

A. Faraj1, S. Desai2, L. Neuman2, G.E Blouse2, T. Knudsen2, U.S. Simonsson1

Abstract Number: PB0458

Dose Selection of Marzeptacog Alfa (Activated) in Children with Hemophilia: A Population Pharmacokinetic Exposure Matching Strategy

A. Faraj1, R. van Wijk1, L. Neuman2, S. Desai2, G.E Blouse2, T. Knudsen2, U.S. Simonsson1

Abstract Number: PB0467

Effects of von Willebrand Factor on Plasma Haemostasis

C. Kluft1, K. Van Leuven1, C. Krijnen1, P. De Kruijf1

Abstract Number: PB0482

Evaluation of Primary Haemostasis in Children and Young Adults with Haemophilia

M. Kürschner1, J. Lohse1, F. Boiti1, O. Tiebel2, R. Knöfler1

Abstract Number: OC 24.1

Evaluation of the Tissue Factor-Independent Mechanism of Action for Eptacog Beta

J.-L. Plantier1, S. Evans2, P. Martres1

Abstract Number: PB0468

Examination and Validation of a Patient-centric Joint Metric: “PROBLEM JOINT”; Empirical Evidence from the CHESS Paediatrics Dataset

T. Burke1, I. Rodriguez Santana1, P. Chowdary2, R. Curtis3, K. Khair4, M. Laffan5, P. McLaughlin2, D. Noone1, B. O'Mahony6, J. Pasi7, M.W Skinner8, J. O'Hara1

  • 1
  • 2
  • 3
  • Next Page »

« View all themes from the ISTH 2021 Congress

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley